CHMP OKs Cell Therapeutics' pixantrone, but reserves view on use after rituximab
This article was originally published in Scrip
The European Medicines Agency's scientific committee, the CHMP, has recommended conditional approval for Cell Therapeutics (CTI Life Sciences) Pixuvri (pixantrone) for relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma as a monotherapy.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.